Peptidergic innervation of guinea-pig brain vessels: comparison with immunohistochemistry and in vitro pharmacology in rostrally and caudally located arteries.
The peptidergic innervation of the guinea-pig basilar artery and the posterior, middle and anterior cerebral arteries were studied by means of immunohistochemical and image analysis techniques using whole mount preparations. An in vitro pharmacological study was performed to correlate the distribution of peptide-containing nerves and the action of neuropeptides on vessel segments from the same vascular regions. The overall distribution of perivascular nerve fibres was demonstrated using an antiserum to the general neuronal marker protein gene product 9.5 (PGP 9.5) and the percentage immunostained area of total vessel wall area occupied by PGP-containing nerves, in each of the basilar, posterior and middle cerebral arteries, was set at 100% and used to determine the relative density of specific populations of autonomic and sensory nerve fibres. In all four cerebral arteries, the majority of nerve fibres possessed neuropeptide Y (NPY) and tyrosine hydroxylase (TH) immunoreactivity, occupying 6.2-13.3% and 5.8-7.5% of the total vessel wall area, respectively. Vasoactive intestinal peptide (VIP), substance P (SP) and calcitonin-gene-related peptide (CGRP) were detected at lower densities. The pharmacological study performed on small circular segments with an intact endothelium revealed that, in all four cerebral arteries, NPY was a more potent constrictor than noradrenaline (NA). The rank order of potency for relaxant agents was CGRP = SP > VIP > ACh in the PCA and MCA, and SP = CGRP > VIP > ACh in the BA and ACA. The correlation between immunostained nerve area and the agonist potency suggested that the denser the peptidergic nerve-supply, the lower the sensitivity to the agonist.
You
J
J
Department of Experimental Research, Lund University, Malmö General Hospital, Sweden.
Gulbenkian
S
S
Jansen Olesen
I
I
Marron
K
K
Wharton
J
J
Barroso
C P
CP
Polak
J M
JM
Edvinsson
L
L
D000818:Animals; D001488:Basilar Artery / Q000737:chemistry / Q000187:drug effects / Q000294:innervation*; D002536:Cerebral Arteries / Q000737:chemistry / Q000187:drug effects / Q000294:innervation*; D019084:Fluorescent Antibody Technique, Indirect; D006168:Guinea Pigs; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000187:drug effects / Q000294:innervation* / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000032:analysis; D009479:Neuropeptides / Q000032:analysis / Q000494:pharmacology / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D013869:Thiolester Hydrolases / Q000032:analysis; D043222:Ubiquitin Thiolesterase; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D009419:Nerve Tissue Proteins; D009479:Neuropeptides; D014662:Vasoconstrictor Agents; D013869:Thiolester Hydrolases; D043222:Ubiquitin Thiolesterase; D009638:Norepinephrine